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ABSTRACT 
Cathepsin G (CatG), a serine protease found in the azurophil granules of 
neutrophils, participates in killing engulfed microorganisms. CatG is a poorly understood 
enzyme, in part because it can only be obtained as mature enzyme purified from human 
blood, and because it seems to have dual specificity for chymotrypsin-like and trypsin-
like substrates. Therefore, yeast Pichia pastoris was used to express immature 
recombinant human CatG to provide a source of the enzyme free of biohazards and to 
allow study of its dual specificity and C-terminal processing. To avoid potential cleavage 
by a yeast kexin protease, the amino sequence was modified without altering CatG’s 
biological activity to remove one glycosylation site and eight dibasic sites. An N-terminal 
6-His-cytochrome B5 (CytB5) heme binding fusion domain was linked to the modified 
human CatG by an enteropeptidase cleavage site for activation. The DNA for this 
construct was codon-optimized and placed in the pPICzα secretion vector. After 
transforming P. pastoris strain X-33, 48 Zeocin-resistant clones were screened for 
relative levels of CatG activity following activation by recombinant human 
enteropeptidase. Recombinant human CatG was partially purified from fermentation 
medium by nickel affinity chromatography and its activity was confirmed by assays 
using the substrate Succinyl-Ala-Ala-Pro-Phe-SBzl. Supported by a Student Faculty 
Collaborative Grant from the ETSU Honors College and ETSU Office of Research and 
Sponsored Programs and by NHLB grant R15HL091770. 
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INTRODUCTION 
 Neutrophils, also known as polymorphonuclear leukocytes, comprise the most 
abundant type of white blood cell in the human body, providing a rapid and localized 
response to infection (Borregaard & Cowland, 1997; Korkmaz et al., 2010). While 
typically found in circulation in the blood stream, neutrophils relocate to sites of 
inflammation in tissues by crossing activated vascular endothelial cells, a process called 
diapedesis (Borregaard et al., 2005). Highly phagocytic neutrophils kill engulfed 
microorganisms by the fusion of granules containing many types of antimicrobial 
peptides, proteases, and reactive oxygen species. While at least four types of granules 
have been described, the azurophil granules, also called primary granules, are 
characterized by the ability to stain with the basic dye azure and by the presence of 
myeloperoxidase (Borregaard & Cowland, 1997). The azurophil granules also contain 
the three neutrophil serine proteases (NSPs) cathepsin G (CatG), human neutrophil 
elastase (HNE), and myeloblastin (elastase-like) along with defensins, bacterial 
permeability-increasing protein, and azurocidin (an inactive member of the serine 
protease gene family) (Borregaard et al., 2005; Pham, 2006). Following phagocytosis of 
the pathogen, the azurophil granules fuse with the phagolysosome and release their 
cytotoxic contents to destroy the invader (Pham, 2006). 
The proteolytic activities of NSPs provide an important non-oxidative mechanism 
for the neutrophil to kill pathogens that resist oxidative attacks (Bangalore et al., 1990). 
It has also been found that the antimicrobial properties of NSPs are not only dependent 
on proteolytic activity but also due to their strong positive charges. Cathepsin G 
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releases charged antimicrobial peptide fragments after being degraded by trypsin-like 
enzymes (Bangalore et al., 1990).  
NSPs also participate in regulation of many inflammatory signaling pathways 
(Pham, 2006). The NSPs process cytokines such as interleukin 6 (IL-6) (Bank et al., 
1999) and chemokines like IL-8 (Padrines et al., 1994). Proteolytic modifications to 
these cytokines and chemokines initiate signaling pathways that can result in both pro- 
and anti-inflammatory responses, as well as the recruitment of various immune cells to 
initiate both the innate and the adaptive immune responses (Padrines et al., 1994; 
Wittamer et al., 2005) 
Neutrophils are protected from the proteolytic activities of their own NSPs by 
storage in the acidic granules as active enzymes; consequently, the release of NSPs 
outside of the neutrophil can pose a serious threat to surrounding tissue. In fact, many 
human diseases have been classified due to improper regulation of NSPs. NSPs are 
capable of degrading collagen and elastin, making them dangerous when exposed to 
connective tissue, especially lung tissue. Some commonly known diseases resulting in 
NSP activity outside the neutrophil are chronic obstructive pulmonary disorder (COPD), 
acute respiratory distress syndrome, and ischemia-reperfusion injury (Korkmaz, Moreau 
& Gauthier, 2008).  
Given the consequences of poorly controlled NSPs there is great interest in 
understanding how NSPs are regulated and directed to the azurophil granules without 
damaging the neutrophil or surrounding tissue. It has been shown that all NSPs are 
synthesized as zymogens in inactive forms as pre-proproteins containing an N-terminal 
signal peptide that directs the protein to the endoplasmic reticulum and a pro-dipeptide 
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that keeps the enzyme in an inactive state until granule maturation (Korkmaz et al., 
2010). It has been shown that the signal peptide is removed by signal peptidase and the 
N-terminal pro-dipeptide by dipeptidyl peptidase I (also called Cathepsin C) (Korkmaz et 
al., 2010). 
In addition to the removal of N-terminal pro-peptides leading to activation, the 
mature NSPs in the azurophil granule are missing C-terminal peptide extensions. By 
studying NSP cDNA it can be seen that the amino acid sequence and length of the           
C-terminal extension varies between CatG, elastase, and myeloblastin. The C-terminal 
peptides do not play a role in activation but are removed during enzyme maturation by 
an unidentified protease (or proteases) (Gullberg et al., 1995). Thus there is some 
interest in studying what removes this C-terminal extension and what function it might 
serve. 
Currently the only available source of the NSPs to study their characteristics is by 
purification from human blood or tissue sources. These purified NSPs are in the mature 
state and be lack the C-terminal pro-peptide, making it nearly impossible to study its 
role in the NSP biosynthesis process. Due to the recent advances in genetics and the 
ability to express homologous proteins in various expression systems, however, there 
exists a potential to genetically engineer an expression system to make an NSP with an 
intact C-terminal extension peptide to aid the study of its biochemical functions.  
While other recombinant NSPs have been expressed in many cell types, the 
expression of full length human CatG has only been reported in RBL cells and murine 
myloid cell line 32D  (Gullberg et al., 1995). CatG has not been reported to be 
expressed in yeast species. CatG is noted for its high arginine content and dual 
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specificity. Using the S1/P1 Schechter-Berger nomenclature, CatG shows both 
chymotrypsin-like P1 specificity and trypsin like-P1 specificity (Fig. 1) (Hof et al., 1996). 
The large, hydrophobic S1 pocket confers chymotrypsin-like specificity for the bulky 
hydrophobic amino acids phenylalanine (as shown) and tyrosine. Trypsin-like specificity 
for positively charged lysine and arginine residues is a result of the negatively charged 
residue glutamate 226 (chymotrypsinogen numbering) at the base of the S1 pocket.  
 
 
Figure 1: Crystal structure of human neutrophil CatG with Suc-VPF-(OPh)2 inhibitor 
(PDB ID: 1CGH). Blue and red regions represent positive and negative charges, 
respectively, while gray regions represent hydrophobic areas. The S1 pocket is labeled 
to show CatG’s catalytic site and dual specificity (Hof et al., 1996). 
 
CatG has a native pI of about 12.0, highest among the NSPs, and contains 34 
arginine residues out of its 224 amino acid length (Hof et al., 1996). The C-terminal 
extension peptide of CatG ranges from 11 to 13 amino acids in length, as the precise 
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cleavage site is not clear. Previous research by crystallographic models of mature CatG 
shows the most common cleavage site to remove the C-terminal extension peptide is at 
serine 244, but one structure reported a C-terminal arginine 243, which suggests the 
possibility of autolysis by CatG (de Garavilla et al., 2005; Greco et al., 2002; Hof et al., 
1996). 
Recombinant expression of CatG has proven to have many challenges. CatG 
shows both antibacterial (Pham, 2006) and antifungal activity (Newman et al., 2000) 
making bacteria species and yeast species questionable expression hosts. While 
expression in insect cells and/or mammalian cells is theoretically possible, these 
expression hosts are not capable of reaching a high cell density and thus could have 
lower expression amounts. Popular bacterial expression hosts, such as E. coli, would 
not be ideal due to CatG’s strong antimicrobial properties by both proteolytic activity and 
by positivity charged amino acid sequences (Bangalore et al., 1990).  The yeast species 
Pichia pastoris was chosen as the expression system due to the eukaryotic protein 
expression, folding, co- and post-translation modification capabilities, and secretion 
mechanisms, relative to prokaryotic expression hosts (Smith, 2013). However to avoid 
CatG’s antifungal activity, recombinant CatG has been designed to include a fusion 
domain at its N-terminus to keep CatG in an inactive zymogen form in the growth 
media.  
Several fusion proteins were used in previous attempts to express CatG, 
including human serum albumin (HSA), enhanced green fluorescent protein (eGFP), 
rubredoxin, and small ubiquitin-like modifying protein (SUMO); however, all expression 
trials with these fusion proteins yielded low expression amounts. Due to previous 
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success expressing HNE with the fusion protein cytochrome B5 (CytB5) heme binding 
domain from the rat species Rattus norvegicus, CytB5 was used as a fusion domain in 
this expression trial. The CytB5 domain was chosen because, when bound to heme, it 
has distinct absorbance at 410 nm and produces visible red color if present in high 
enough concentration (Mitra et al., 2005). Thus the CytB5 fusion protein can be traced 
spectrophotometrically at 410 nm and visually during the purification and processing 
steps. The fusion design (Fig. 2) also contains a six histidine (6His) sequence at the N-
terminal of the CytB5 domain to aid in purification. To link the C-terminus of the CytB5 
domain and the N-terminus of the CatG domain, a FLAG tag linker with the sequence 
DYKDDDDK is included that is capable of being cleaved by enteropeptidase (EP) after 
the lysine to expose CatG’s native N-terminus (Fig. 2). 
 
 
Figure 2: A) Block diagram showing the fusion protein design of Cathepsin G and 
cytochrome B5 with a six histidine tag for purification and FLAG tag for specific 
cleavage by enteropeptidase to separate the domains after purification. B) Activation 
schematic showing enteropeptidase cleaves after lysine in the FLAG tag to release the 
two domains and activate human recombinant Cathepsin G. 
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The amino acid sequence of Cathepsin G was modified in an attempt to enhance 
expression in P. pastoris. Arginines (R) were replaced with glutamines (Q) at 8 sites to 
reduce the net positive charge on CatG and to block potential cleavage by the 
endogenous yeast Kex2 protease, used in the secretory mechanism (Fig 3). While 
glutamine is uncharged it maintains arginine’s general shape, so the pI of the protein 
should be decreased while its overall structure and function theoretically should not be 
dramatically affected. The other amino acid substitution made was a glutamine (Q) for 
an asparagine (N) to block a potential N-linked glycosylation site, as yeast species are 
known to hyperglycosylate proteins (Niles et al., 1998). 
 
 
Figure 3: Sequence alignment of native CatG (bottom rows) and recombinant human 
CatG (top rows). Eight amino acid substitutions (blue) were made from arginine (R) to 
glutamine (Q) to reduce overall pI of CatG and avoid potential cleavage by yeast 
internal protease Kex2 in attempts to enhance expression. The other mutation of 
asparagine (N) to glutamine (Q) was made to block potential a glycosylation site. The C-
terminal pro-peptide extension is highlighted in red. 
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The resulting amino acid sequence was then combined with the cytochrome B5 
domain, FLAG tag and 6His tag to give the overall amino acid sequence (Fig. 4). The 
cDNA for this amino acid sequence was codon optimized for P. pastoris to optimize 
expression by using the codons that appear most frequently in the P. pastoris genome. 
 
 
Figure 4: Amino acid sequence of full length 6His-CytB5-FLAG-CatG. The 6His 
sequence is shown in red and following it is the cytochrome B5 domain. The FLAG tag 
linker is shown in blue. The recombinant human CatG gene is shown after the FLAG tag 
with its C-terminal pro-peptide extension underlined in red. 
 
The resulting DNA sequence of codon optimized 6His-CytB5-FLAG-CatG was 
ligated into the pPICzα plasmid from Invitrogen (Fig. 5). This plasmid was chosen 
because of its alpha factor domain that signals for secretion of the fusion protein into 
growth media for easy recovery and the production is regulated by the methanol-
inducible AOX1 promoter. The Zeo(R) gene confers Zeocin resistance, making 
selection for transformed colonies possible on Zeocin treated plates. This plasmid was 
linearized and introduced to the yeast genome by electroporation and sequential 
homologous recombination. 
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Figure 5: The pPICzα plasmid with the 6His-CytB5-FLAG-CatG ligated. Key features of 
the plasmid include the expression of the alpha factor that signals for secretion, the 
methanol-inducible AOX1 promoter and the Zeo(R) gene that gives the P. pastoris 
resistance to Zeocin for selection of transformed cells. 
 
MATERIALS AND METHODS 
MOLECULAR CLONING / TRANSFORMATION / SCREENING 
The molecular cloning, transformation, and expression screening for CytB5 CatG 
were performed by Dr. Eliot Smith and all credit is thereby given to his efforts (Smith, 
2013). The native amino acid sequence for Homo sapiens CatG (NP_001902.1) and the 
soluble, heme-binding domain of Rattus norvegicus cytochrome B5 (NP_071581.1) 
were obtained from the National Center for Biotechnology Information (NCBI). The 
sequences were aligned and modified in the computer software Geneious ® 6.1.4. In 
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the CatG sequence, amino acid mutations were made by replacing asparagine with 
glutamine at position 65 and replacing arginine with glutamine at positions 76, 86, 111, 
114, 148, 178, 186 and 188. Codons for the FLAG tag sequence (DYKDDDDK) were 
added to the 5’ end of the Cathepsin G gene. The resulting recombinant human CatG 
(rhCatG) sequence was codon optimized (GenScript) for expression in P. pastoris and 
provided in the sub-cloning plasmid pUC57 with 5’ KpnI and 3’ NotI restriction sites 
flanking the FLAG-CatG sequence. A 6Hisamino acid sequence was added to the N-
terminus of the CytB5 domain. This sequence was codon optimized (GenScript) and 
provided in a separate pUC57 sub-cloning plasmid with the gene flanked by restriction 
sites 5’ XhoI and 3’ KpnI. The pUC57 sub-cloning plasmids were introduced to Zymo 
DH5α “Easy Comp” E. coli for stock and were purified for further cloning by miniprep 
purification technique (Zymo Research). 
The plasmids were treated with their corresponding restriction enzymes (Thermo 
Scientific, Fermentas FastDigest®) and the desired bands were recovered by gel 
extraction using the Zymoclean™ gel DNA recovery kit (Zymo Research). The ligation 
process happened in two-steps where the pPICzα and pUC57-6His-CytB5 plasmids 
were cut with XhoI and KpnI and mixed and ligated with Quick Stick Ligase (Bioline) 
resulting in the insertion of the 6His-CytB5 gene into the pPICzα plasmid. This resulted 
ligated pPICzα-6His-CytB5 plasmid was cloned into DH5α E. coli. For the final ligation 
the pPICzα-6His-CytB5 and pUC57-FLAG-rhCatG plasmids were cut with restriction 
enzymes KpnI and NotI and mixed resulting in the ligation to form the desired the 
pPICza-6His-CytB5-FLAG-rhCatG plasmid which was again cloned into DH5α E. coli. 
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The presence of the insert was confirmed by amplification by PCR and the size was 
confirmed using gel electrophoresis. 
Transformation was done per the EasySelect™ Pichia Expression Kit and 
protocol (Life Technologies). The plasmid was linearized for electroporation by the 
restriction enzyme BstXI. The linearized plasmid was further purified by a DNA cleanup 
Kit (Zymo Research). The purified plasmid was then concentrated by precipitating the 
DNA with ethanol, then evaporating the ethanol and resuspending the DNA in a small 
amount of nuclease free water. Purified pPICzα-6His-CytB5-FLAG-rhCatG plasmid was 
electroporated into P. pastoris strain X-33 cells by the Life Technologies electroporation 
protocol using a 2 mm gap cuvette and BTX ECM 600 electroporation system, with the 
settings of 1.5 kV and 186 Ω producing a 7.5 millisecond pulse length. Successful 
transformants were selected by plating on YPDS (10 g/L yeast extract, 20 g/L peptone, 
182.2 g/L sorbitol, 2% glucose) agar plates treated with 100 μg/mL Zeocin™ (Life 
Technologies) and 100 μg/mL ampicillin. Colonies that showed resistance to Zeocin™ 
were transferred to numbered location spots on fresh YPD agar plates with 100 μg/mL 
Zeocin™ and 100 µg/mL ampicillin. 
 To screen for enzyme production, 44 colonies were picked and grown in 2 mL 
cultures in 12-well plates. The cells were grown in synthetic minimal medium (SMM) (10 
g/L monosodium glutamate (MSG), 2.5 mg/L ammonium sulfate (NH4)2(SO4), 1.34% 
yeast nitrogen base, 4 x 10-5% biotin, 100 mM potassium phosphate (KH2PO4),           
pH = 5.0) with 100 μg/mL of both Zeocin™ and ampicillin. The 12-well plates were 
placed on an orbital shaking platform and grown at 25 °C for 4 days. The cultures 
received 1% feedings of methanol at inoculation and every 24 hours after. After 4 days, 
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the cells were harvested by centrifugation. The supernatants were removed from the 
cell pellets and screened for activity. The cell pellets were weighed to give a wet cell 
weight (WCW) for quantification by comparison of the culture activity per gram WCW. 
 
FERMENTATION 
The fermentation was run in a BioFlo 110 bioreactor with 7.5 liter capacity (New 
Brunswick). The fermentation vessel was equipped with a pH probe and dissolved 
oxygen (dO2) sensor (Mettler-Toledo) to monitor culture conditions. The most successful 
growth medium employed the basal salts medium (BSM) (26.7 mL/L phosphoric acid 
(H3PO4), 0.93 g/L calcium phosphate (CaSO4), 18.2 g/L dipotassium phosphate 
(K2SO4), 14.9 g/L magnesium sulfate heptahydrate (MgSO4*7H2O), 40 g/L glycerol) 
suggested by Life Technologies. BSM was supplemented with 10 g/L MSG and 1 mL/L 
PTM4 trace element supplements ( 2 g/L CuSO4*5H2O, 0.08 g/L NaI, 3.0 g/L        
MnSO4 * 2H20, 0.2 g/L Na2MoO4 * 2H20, 0.02 g/L H3BO3, 0.5 g/L CoCl2, 7 g/L ZnCl2,    
22 g/L Fe(II)SO4 * 7H2O, 0.2 g/L Biotin, 1 mL/L H2SO4, 0.5 g/L CaSO4 * 2H2O) (Stratton, 
Chiruvolu & Meagher, 1998). A supplementary vitamin mix was also added from a 10X 
concentrate containing 0.1 g/L L-His-HCl, 0.2 g/L DL-Met, 0.2 g/L DL-Trp,             
0.0002 g/L biotin, 0.0002 g/L folic acid, 0.2 g/L inositol, 0.04 g/L niacin,                      
0.02 g/L p-aminobenzoic acid, 0.04 g/L pyridoxine HCl, 0.02 g/L riboflavin, 0.04 g/L 
thiamine HCl, 0.04 g/L calcium pantothenate, and 10 g/L CaCl2. 
BSM was assembled in the fermentation vessel with calculations made for a final 
volume of 3.5 liters at the time of inoculation. While the amounts of ingredients were 
added for 3.5 liters, only 2.5 liters of volume was added due to the fact other ingredients 
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would be added after the medium was autoclaved. After the autoclaving process and 
once the medium was cooled, 15 mL of filter-sterilized PTM4 salts and 35 mL of filter-
sterilized 100X vitamin mix. The fermenter vessel was hooked up to an oxygen tank and 
the oxygen probe was calibrated by achieving 100% dO2 with a blast of oxygen at         
4 L/min and 1200 RPM. The pH probe was calibrated using pH = 4 and pH = 7 buffering 
solutions. X-33 P. pastoris colony #43 containing the incorporated pPICzα-6xHis-CytB5-
FLAG-CatG vector was grown two days before inoculation in a 10mL “seed” culture 
containing 10mL YPD with 100 μg/mL Zeocin and ampicillin. Then the seed culture was 
used to inoculate a fresh 500mL culture containing SMM media with glycerol. This 500 
mL starter culture was allowed to grow overnight and was then used to inoculate the 
fermenter. 
To prepare for inoculation the air flow was turned down to 0.4 L/min and the 
fermenter was hooked up with a feed of 12.5 % ammonia controlled by variations in the 
pH readings. The initial medium was intentionally placed at very low pH (pH < 2) with 
phosphoric acid so that the pH was raised by the addition of ammonia (approximately 
250 mL) before inoculation to give the cells both a phosphate source (phosphoric acid) 
and nitrogen (ammonia) source to start the fermentation process. As the cells 
metabolize the carbon source the pH of the media decreases; consequently, the auto 
adjustment of pH by ammonia allows for constant addition of nitrogen source for the 
cells. Approximately 200 mL of sterile ultrapure water was added to the medium to bring 
the volume to 3 liters. The fermentation medium was inoculated with 500 mL of the 
starter culture bringing the final volume to 3.5 L.  
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The fermentation was run in three distinct phases. The glycerol fed-batch phase 
allowed the cells to exhaust the 40 g/L glycerol already present in the fermentation 
media. During the glycerol fed-batch phase, the cells were fed a 40% (w/v) glycerol 
solution drop wise at 1 mL/min to increase cell density and to ensure that the culture 
was carbon-limited. Daily 25 mL samples were collected for centrifugation and analysis. 
The supernatant was removed and cell pellet was weighed to monitor cell density. 
When the fermenter had reached sufficient density the culture was transitioned to 
methanol to start the methanol fed-batch phase to induce expression of the 6His-FLAG-
rhCatG. Drop wise addition of 95% Methanol with 5 mL/L PTM4 was introduced 
following Life Technologies protocol. The addition of methanol had to be carefully 
monitored as the accumulation of too much methanol can be toxic to the cells. The cell 
density was monitored as well as spikes in the dO2 content when adjusting the 
methanol feed rate. The cells were grown until they entered stationary phase when the 
weight cell weight leveled off. The cells were harvested at 140 hours post-induction by 
centrifugation. The supernatant was pooled and kept for further processing while the 
cell pellets were discarded. 
 
TREATMENT OF MEDIUM 
Two liters of fermentation medium was filtered first by glass fiber pre-filters 
(Millipore Cat#AP2004200) then by 0.45 µm regenerated cellulose filters (Pall P/N 
60173). Clarified medium was then concentrated by ultrafiltration using two 10 kDa 
molecular weight cut off tangential flow filtration cartridges (Sartorius Vivaflow50 P/N 
VF05P0) in series. Once concentrated to approximately 50 mL, the medium was diluted 
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1:20 with 500 mM acetic acid (pH unadjusted) to eliminate phosphate and calcium that 
would otherwise precipitate at pH levels above 5. After two 1:20 dilutions with acetic 
acid, the solution was further diluted three times using a 1:20 dilution each time with 
IMAC equilibration buffer (25 mM sodium phosphate, 300 mM NaCl, pH = 8). The 
sample was then concentrated to approximately 50 mL to be loaded on an IMAC 
column for purification. 
 
PURIFICATION (IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY) 
The column was set up using Profinity™ Ni2+ IMAC Resin (Bio-Rad) resin 
suspended in IMAC equilibration buffer. The column was loaded with the concentrated 
fermentation sample at 1 mL/min. The flow through from the loaded sample was 
collected in a clean container. After all the sample had been loaded, the column was 
washed with IMAC Wash Buffer (200 mM sodium phosphate, 300 mM NaCl, 5 mM 
imidazole, pH = 8) at a rate of 5 mL/min. The wash step flow through volume was 
collected in 5 mL fractions to watch for the A280 and A410 peaks. For the elution step, 
the IMAC Elution Buffer (200mM sodium phosphate, 300 mM NaCl, 20 mM imidazole at 
pH = 8) was loaded at a rate of 2 mL/min into 2 mL fractions. To monitor protein elution 
an absorbance spectrum on 100 µL of each fraction sample was measured from 250 
nm to 600 nm using a Biotek PowerWave™ XS2 plate reader. The resulting absorbance 
values at 280nm and 410nm were recorded.  
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SAMPLE ACTIVATION BY ENTEROPEPTIDASE 
For all liquid enteropeptidase (EP) activations 100 µL of the sample of interest 
was combined with 2 µL of EP. The sample was then incubated in a 37 °C water bath 
for 24 hours. 
 
ACTIVITY ASSAYS 
All assays testing for the activity of rhCatG were performed using the synthetic 
substrate Suc-AAPF-SBzl (LifeTein custom synthesis). This synthetic substrate is 
cleaved by CatG after the phenylalanine and the benzyl-thiol is released which then 
outcompetes for one of the substituted benzene rings on DTNB (Fig 6). The displaced 
substituted benzene generated as the final product in the reaction produces a yellow 
color and has a defined extension coefficient at 410 nm (ε410 nm = 13600 M
-1 cm-1) and 
by monitoring its absorbance over time, the amount of activity can be quantified 
(Johnson, 2006). 
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Figure 6: Synthic substrate succinyl-AAPF-thiobenzyl ester used to measure the 
activity of CatG. CatG is specific to cleave after the phenylalanine (F) and results in the 
release of the benzyl-thiol group which out completes one of the substitutive containing 
benzene rings releases a carbo,nitro benzene ring that produced yellow color and 
absorbance can be tracked spectrophotometrically at 410 nm over time (Johnson, 
2006). 
 
The assay conditions were in a 100 µL total volume reaction in 96-well plates in 
the Biotek PowerWave™ XS2 plate reader which monitored the increasing absorbance 
at 410 nm every 30 seconds for a 10 minute total assay time. Each sample contained 
25 µL of CatG Assay Buffer (100 mM HEPES, 1 M NaCl, 10 % glycerol, 0.01 % Triton 
X-100, and 0.01 % NaN3 at pH = 8.0). To the buffer, 25 µL of sample containing rhCatG 
was added. Immediately before the assay was started, 50 µL of substrate buffer (300 
µM Suc-AAPF-SBzl, 100 mM DTNB in CatG assay buffer) was added to bring the 
reaction volume to 100 µL. 
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DOT BLOT 
The dot blot was prepared by pipetting very small volumes on a dry piece of 
nitrocellulose membrane. Human purified CatG was loaded in amounts of 2 μg, 0.5 μg, 
0.1 μg, and 0.05 μg to serve as CatG positive controls for the primary antibody. Also 
blotted was a 10 μL sample from the IMAC purified pooled 6His-CytB5-FLAG-CatG 
sample. To test the primary rabbit-anti-CatG polyclonal IgG antibody and secondary 
HRP-conjugated goat-anti-rabbit IgG polyclonal antibody efficacy 2 μL of a 1:4000 
dilution was blotted to the membrane. Two samples of secondary antibody were tested 
on the blot and the second (#2) was used to develop the blot. After loading the samples 
the nitrocellulose membrane was blocked overnight in a 1% BSA solution in TBST (10 
mM Tris, 150 mM NaCl, 0.05% Tween20 pH= 7.5) at 4 °C. After 24 hours, the blot was 
rinsed with 25 mL of TBST 4 times and the blot was allowed to sit in the primary 
antibody (CatG-anti-rabbit) at a 1:4,000 dilution in TBST overnight at 4 °C. After another 
24 hours the blot was rinsed with 4 more rinses of 25 mL TBST. The secondary 
antibody #2 (HRP-anti-rabbit) was added at a 1:4,000 dilution in TBST and was allowed 
to react for 1 hour at 4 °C. The membrane was rinsed with the 4 washes of TBST. The 
image was exposed to HRP ECL SuperSignal® West Pico Chemiluminescent Substrate 
(Thermo) immediately prior to imaging.  
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RESULTS 
FERMENTATION CELL DENSITY 
The large scale growth of the best expressing clone of rhCatG #43 yielded a final 
cell density of approximately 225 g/L with a final volume of approximately 6 liters (Fig. 
7). The culture was on the glycerol fed-batch phase until a cell density of 140 g/L was 
reached. The culture was then transitioned to the methanol fed-batch phase after 77 
hours post inoculation. The cells reached a final density of 225.76 g/L before the culture 
growth leveled off in stationary phase at 140 hours post inoculation. 
 
Figure 7: Fermentation cell density graph in units of wet cell weight (WCW) in g/L 
verses the time in hours. The culture grew to sufficient density (140 g/L) on glycerol 
during the glycerol batch phase and glycerol fed batch phase. The culture was 
transitioned to the methanol fed batch phase (i.e. induced) after 77 hours post 
inoculation. The culture expanded for 120 hours before entering stationary phase.  The 
culture was harvested 140 hours post-inoculation at a final cell density of 225.76 g/L. 
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CATG ACTIVATION 
Supernatants from the fermentation medium were tested for CatG activity using 
the synthetic peptide substrate suc-AAPF-SBzl. The results consisted of a positive 
control of native CatG purified from human blood neutrophils and a negative control 
without CatG to check for substrate autolysis. An activity assay (Fig. 8) confirmed the 
presence of activatable CatG in the fermentation medium and the increase in activity 
between the sample before activation and the activated sample was 6 fold. The media 
before activation still had some activity towards the synthetic substrate, suggesting that 
either some rhCatG is auto-activating in the fermentation media or that Pichia pastoris is 
secreting a yeast chymotrypsin-like enzyme. A separate control sample containing only 
EP produced minimal activity (< 20 mA410) (data not shown) and its contribution, if any, 
to the overall activity was negligible in these assays. 
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Figure 8: Fermentation media supernatant screened for activity using suc-AAPF-SBzl 
substrate. Positive control native CatG (purple) displays activity against the synthetic 
substrate while the negative control with no enzyme added serves as a blank. The 
activated sample (red) has approximately 6-fold greater activity than the equivalent 
sample prior to activation (green), confirming expression of the activatable 6His-CytB5-
FLAG-rhCatG fusion protein design. 
 
 
IMAC COLUMN 
The expressed 6His-CytB5-FLAG-rhCatG fusion protein in the fermentation 
medium supernatant was purified by its 6His tag using a nickel IMAC column. The 
concentrated fermentation medium supernatant for the rhCatG clone was consistently a 
dark green color that is abnormal compared to other fermentation media from parallel 
serine protease expression projects. While most of the green color was seen in the flow 
through, some of the color adsorbed to the column and eluted with 20 mM imidazole 
(Figure 10). 
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Figure 10: The elution front during step of the IMAC purification as tracked by the green 
color coming off the column during the elution step using 20mM imidazole buffer.  
 
The green color was seen in the wash buffer and in the elution fractions; 
however, after fraction 33 the fractions shifted from a green color to a brownish color. 
This shift in color was also detected spectrophotometrically by an absorbance spectrum 
250 nm to 600 nm of each fraction and fraction #36, with the highest 410 nm 
absorbance, had three distinct peaks at 280 nm, 350 nm, and 410 nm (Fig. 11). The 
280 nm and 410 nm absorbance peaks correspond to the general protein absorbance at 
280 nm and the CytB5 absorbance at 410 nm: however, the peak absorbance at 350 
nm was not expected and could be due to the green color seen co-eluting with the 
fusion protein.  
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Figure 11: Spectrophotometric absorbance spectrum from 250 nm to 600 nm in 5 nm 
increments of fraction #36 from the IMAC purification column. Three distinct peaks were 
present at 280 nm, 350 nm, and 410 nm. The absorbance peak at 350 nm is from an 
unidentified contaminate protein that was seen to have a green color and was found to 
co-elute with the 6His-CytB5-FLAG-CatG fusion protein (Smith, 2013). 
 
Absorbance values at 280 nm and 410nm were plotted along with the activity of 
each fraction to produce an elution profile (Fig 12). It can be seen from the elution 
profile that the activity purified partially in fractions 32 through 39. This spike in activity 
accompanies the peak in absorbance at 280 nm and a slight peak at 410 nm. The 280 
nm absorbance values from fractions 24 to 32 correspond to some unidentified protein 
that is co-eluting with 6His-CytB5-FLAG-CatG and from the appearance of the fractions 
it appears to be the protein also responsible for the green color and absorbance at 350 
nm in the wavescans. Fractions 32 through 39 were pooled for further processing. 
 
  Perry 26 
 
  
Figure 12: The elution profile from nickel IMAC purification of the 6His tag on the 
rhCatG fusion protein design. The absorbance at 280 nm (blue) and 410 nm (red) is 
graphed with the absorbance scale on the left and activity scale on the right. The activity 
(green) is graphed against its absorbance at 410 nm over time from activation assays. 
The high A280 readings from fractions 24-35 indicate another protein is co-purifying 
with the 6His-CytB5-FLAG-CatG fusion protein. The active fractions 32 through 39 were 
pooled. 
 
 
DOT BLOT 
After several failed Western blots with no signal produced from the partially 
purified 6His-CytB5-FLAG-CatG fusion protein and native CatG positive control, a dot 
blot was preformed to test for the efficacy of our primary and secondary antibodies. 
Native CatG samples were loaded to test for antibody signal, along with blotting the 
primary rabbit anti-CatG antiserum (Athens Research & Technology) and two 
secondary HRP-conjugated goat anti-rabbit polyclonal antibodies directly to the 
nitrocellulose membrane. Finally, a sample from the pooled IMAC fractions was also 
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analyzed. The results (Figure 13) prove that secondary antibody 1 (Proteintech) that 
had been used in the Western blotting attempts was not able to produce signal. The 
secondary antibody 2 (Pierce Biotechnology) functioned as expected in this dot blot. 
 
 
 
Figure 13: Dot blot testing the effectiveness of our secondary antibodies, signal 
strength from a series of dilutions of CatG, and a sample of IMAC purified 6His-CytB5-
FLAG-CatG. The only spot that did not show signal was the secondary antibody 1 
(ProteinTech). The 6His-CytB5-FLAG-CatG signal was much weaker than the 500 ng 
sample of CatG suggesting a very small amount of expressed and purified 6His-CytB5-
FLAG-CatG. 
 
 
 
CONCLUSIONS 
 Large scale fermentation of P. pastoris transformed with 6His-CytB5-FLAG-
rhCatG resulted in the secretion of activatable rhCatG in the growth media, but in very 
low amounts (µg/L). The activatable fusion protein was able to be partially purified with 
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Ni2+ IMAC column and its elution was shown to correlate with absorbance readings at 
280 nm and 410 nm as well as by activity for each fraction. A green colored protein from 
the media, however, was seen to co-elute with our rhCatG fusion protein, especially in 
the early fractions and it is thought to have an absorbance at 350 nm. A likely candidate 
for the identity of the green protein is alcohol oxidase 1 that is being expressed under 
the AOX1 promoter as the green color in the fermentation medium accumulates after 
the addition of methanol.  After the sequential purification steps that would be needed to 
further purify rhCatG fusion protein from the green contaminate protein the final amount 
of rhCatG would be too little to do kinetic analysis, characterization, and further 
experiments with the C-terminal extension peptide.  
The problem of low expression and troubleshooting at the purification step has 
been a reoccurring theme with the CatG project as similar fusion protein designs have 
yielded similar results. CatG’s antifungal activity does not seem to be an issue due to 
the fact that the yeast cells grow sufficient and in a linear fashion as expected. The 
expression and secretion mechanisms of P. pastoris could be getting clogged, due to 
the challenge of keeping up with the demand of expression of CatG due to its high pI. In 
the neutrophil elastase project it was seen that the P. pastoris cells had a pink color and 
when the cells were lysed only minimal elastase activity was seen. Thus it could be 
entirely possible that the CytB5 domain is being expressed first (N-terimus) and 
expression is halted due to troubles in expression of the serine proteases. Another 
possibility of low expression could be enzyme degradation in the media by yeast 
secreted proteases. As these causes are merely speculation, further experimentation is 
needed to provide insight to the cause of low expression and thus bettering attempts to 
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enhance the expression of neutrophil serine proteases. Further studies should be done 
using qPCR to determine mRNA levels. By knowing the mRNA levels it could be 
determined if the low protein expression was due to the transcription/translation process 
or due to posttranslational degradation. By using the functional secondary antibody, 
further tests should be done by western blots to confirm the molecular weight and 
presence of rhCatG through the expression, purification, and activation steps. 
 This project using the CytB5 fusion domain has provided us with ideas for 
designing alternative expression constructs.  Subsequent studies will employ attempted 
expression of an N-glycosylated rhCatG in hope of improving secretion and will use a 
newer P. pastoris strain SuperMan5 (Biogrammatics) instead of X-33 P. pastoris, which 
tend to hyperglycosylate proteins.  SuperMan5 has been engineered to provide 
glycosylation patterns similar to those of human cells. The next fusion protein to try is a 
prancer purple colored protein (DNA 2.0). Prance purple protein is known for its distinct 
purple color, instead of the red color of CytB5. Instead of using a 6His tag, a 10His tag 
is being engineered at its N-terminus to enhance the binding to the Ni2+ IMAC column 
for better separation during purification. Additionally, expression of this new fusion 
protein gene construct will be placed under control of the constitutively active GAP 
promoter thus the fusion protein will be expressed and secreted at all times. It is thought 
that slower and constant expression will result in better secretion of the 10His-
PrancerPurple-FLAG-rhCatG fusion.  Without the need for transitioning to the methanol 
fed-batch phase the cells can theoretically grow to a higher density on glycerol as the 
sole carbon source from start to finish and produce more secreted product (Love et al., 
2012). This new 10His-Prancer-FLAG-rhCatG fusion protein design has been 
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successfully ligated into the pJ915 plasmid and has been electroporated into the 
SuperMan5 P. pastoris. Expression trials for this construct are currently in process. 
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